Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Samoilova, O; Novak, J; Ben-Yehuda, D; Strugov, V; Gill, D; Gribben, JG; Hsu, E; Lih, CJ; Zhou, C; Clow, F; James, DF; Styles, L; Flinn, IW; Lancet Oncol. 2019; 20(1): 43-56.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal, F; Bjelic-Radisic, V; Knauer, M; Steger, G; Hubalek, M; Balic, M; Singer, C; Bartsch, R; Schrenk, P; Soelkner, L; Greil, R; Gnant, M Ann Surg. 2019; 269(6):1163-1169

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.

Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R; J Clin Med. 2019; 8(7):

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.

Zaborsky, N; Gassner, FJ; Höpner, JP; Schubert, M; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Egle, A; Leukemia. 2019; 33(4):957-968

Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding – a case report.

Mirna, M; Lichtenauer, M; Theurl, T; Ausserwinkler, M; Topf, A; Westphal, T; Gampenrieder, SP; Pretsch, I; Greil, R; Hoppe, UC; Scott Med J. 2019; 64(4):142-147

Prediction of Distant Recurrence Using EndoPredict Among Women with ER

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M; Clin Cancer Res. 2019; 25(13): 3865-3872.

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Singer, CF; Filipits, M; Jahn, SW; Abete, L; Jakesz, R; Greil, R; Bauernhofer, T; Kwasny, W; Seifert, M; Fitzal, F; Kastner, M; Schmitt, M; Moinfar, F; Gnant, M BREAST. 2019; 46: 101-107.

Obituary for Professor Michael Steurer

Egle, A; MEMO-MAG EUR MED ONC. 2019; 12(2): 103-104.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wöhrer, S; Wölfler, A; Gisslinger, H; Wien Klin Wochenschr. 2019; 131(1-2):47

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A; Eur J Haematol. 2019; 102(5): 437-441.